Cardinal Health (CAH)
(Delayed Data from NYSE)
$94.10 USD
-0.36 (-0.38%)
Updated Jul 12, 2024 03:59 PM ET
After-Market: $94.12 +0.02 (0.02%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$94.10 USD
-0.36 (-0.38%)
Updated Jul 12, 2024 03:59 PM ET
After-Market: $94.12 +0.02 (0.02%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth A Momentum A VGM
Zacks News
3 Reasons to Hold Inogen (INGN) Stock in Your Portfolio for Now
by Zacks Equity Research
Inogen's (INGN) potential in the POC space and a strong product portfolio raise optimism about the stock.
Teleflex (TFX) Q4 Earnings Top Estimates, Operating Margin Falls
by Zacks Equity Research
Teleflex (TFX) surpasses earnings and revenue estimates in the fourth quarter of 2023.
Best Growth Stocks to Buy for February 23rd
by Zacks Equity Research
CAH, POWL and PAX made it to the Zacks Rank #1 (Strong Buy) growth stocks list on February 23, 2024.
Best Value Stocks to Buy for February 23rd
by Zacks Equity Research
BLDR and CAH made it to the Zacks Rank #1 (Strong Buy) value stocks list on February 23, 2024.
Veracyte's (VCYT) Q4 Loss Widens, Gross Margin Expands
by Zacks Equity Research
Veracyte's (VCYT) fourth-quarter 2023 performance reflects solid financial discipline and the strength of the Decipher Prostate and Afirma tests.
Best Income Stocks to Buy for February 23rd
by Zacks Equity Research
AROC, JSAIY and CAH made it to the Zacks Rank #1 (Strong Buy) income stocks list on February 23, 2024.
New Strong Buy Stocks for February 23rd
by Zacks Equity Research
IRDM, JSAIY, CAH, LNTH and CENTA have been added to the Zacks Rank #1 (Strong Buy) List on February 23, 2024.
ICON (ICLR) Q4 Earnings Surpass Estimates, Margins Expand
by Zacks Equity Research
ICON's (ICLR) solid performance in the fourth quarter reflects continued market leadership across customer segments it serves.
Better Therapeutics' (BTTX) CBT Gains FDA's Breakthrough Status
by Zacks Equity Research
Better Therapeutics' (BTTX) novel CBT platform attains the FDA's breakthrough device designation to improve patient care in the treatment of liver and metabolic diseases.
Nevro's (NVRO) Q4 Earnings and Sales Top Estimates, Margins Up
by Zacks Equity Research
Nevro's (NVRO) fourth-quarter earnings and revenues surpass their respective consensus estimate. The company incurs a loss in the operating level.
Exact Sciences (EXAS) Q4 Loss Narrows, Revenues Rise Y/Y
by Zacks Equity Research
Robust revenues from Exact Sciences' (EXAS) Screening and Precision Oncology segments contribute to the fourth-quarter top line.
Why Cardinal Health (CAH) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Glaukos (GKOS) Q4 Earnings Miss Estimates, Revenues Rise Y/Y
by Zacks Equity Research
Glaukos' (GKOS) fourth-quarter revenues beat estimates as well as gained year over year. Gross margin improve, while higher operating expenses lead to a wider operating loss.
Tandem Diabetes (TNDM) Posts Wider Q4 Loss, Gross Margin Down
by Zacks Equity Research
Tandem Diabetes (TNDM) reports a higher-than-expected loss in the fourth quarter of 2023.
5 Stocks Favored by Brokers Amid the Current Uncertainty
by Maharathi Basu
We believe that stocks like Deutsche Bank (DB), Cross Country Healthcare (CCRN), Bread Financial (BFH), American Axle (AXL) and Cardinal Health (CAH) should be on an investor's watchlist.
Here's Why You Should Retain Align Technology (ALGN) Stock Now
by Zacks Equity Research
Investors are optimistic about Align Technology (ALGN) on continued geographic expansion.
Boston Scientific (BSX) Surges 4.6%: Will the Rally Continue?
by Zacks Equity Research
Boston Scientific (BSX) is benefitting from an impressive gain in MedSurg market share and the strong adoption of WATCHMAN FLX.
Charles River (CRL) Gains From CRADL Amid Soft Market Scenario
by Zacks Equity Research
Within DSA, Charles River (CRL) is currently the largest provider of outsourced drug discovery, non-clinical development and regulated safety testing services worldwide.
Sight Sciences (SGHT) to Expand in Europe With New Launch
by Zacks Equity Research
By tapping into the European market, Sight Sciences (SGHT) aims to capitalize on the growing demand for advanced eye care technologies.
Avanos (AVNS) Q4 Earnings Lag Estimates, Margins Contract
by Zacks Equity Research
Despite strength in Avanos' (AVNS) Digestive Health segment, its overall fourth-quarter results reflect soft performances.
Here's Why You Should Buy Zimmer Biomet (ZBH) Stock Now
by Zacks Equity Research
Strategic plans to drive the Knee business bode well for Zimmer Biomet (ZBH).
Globus Medical (GMED) Q4 Earnings Surpass, Margins Down
by Zacks Equity Research
Globus Medical's (GMED) fourth-quarter 2023 performance benefits from innovative launches across its product groups.
Medtronic (MDT) Q3 Earnings Beat Estimates, 2024 View Up
by Zacks Equity Research
Medtronic's (MDT) third-quarter organic growth reflects broad strength across businesses and geographies.
Here's Why Investors Should Retain ResMed (RMD) Stock for Now
by Zacks Equity Research
Investors are optimistic about ResMed's (RMD) increased adoption of AirSense10 and AirSense11 devices.
GE HealthCare's (GEHC) Tie-Up to Improve Care Accessibility
by Zacks Equity Research
GE HealthCare's (GEHC) latest alliance is likely to include investment in new technology systems, digital tools and resources, service and support across a variety of care areas.